Evidence map›Paper›PMID 19447387›Full record

Trial reportAtherosclerosis2009

Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS).

Shinichi Oikawa, Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito, Yuichi Ishikawa, Jun Sasaki, Hitoshi Hishida, Hiroshige Itakura and 7 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Atherosclerosis, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 11 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 11 syntheses or guidelines pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Marine-derived n-3 fatty acids therapy for stroke.The Cochrane database of systematic reviews · 2022
    Pooled it
  3. Pooled it
  4. Marine-derived n-3 fatty acids therapy for stroke.The Cochrane database of systematic reviews · 2019
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Statins for the primary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2013 · on this map
    Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Review
  17. Do patients benefit from omega-3 fatty acids?Cardiovascular research · 2024
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 14 institutions in 1 country.

Shinichi OikawaNippon Medical School, Department of Medicine, 1-1-5 Sendagi, Bunkyoku, Tokyo 113-8603, Japan. shinichi@nms.ac.jp
Mitsuhiro Yokoyama
Hideki Origasa
Masunori Matsuzaki
Yuji Matsuzawa
Yasushi Saito
Yuichi Ishikawa
Jun Sasaki
Hitoshi Hishida
Hiroshige Itakura
Toru Kita
Akira Kitabatake
Noriaki Nakaya
Toshiie Sakata
Kazuyuki Shimada
Kunio Shirato
JELIS Investigators, Japan
Chiba University · JPFujita Health University · JPHyogo Prefectural Awaji Medical Center · JPIbaraki Christian University · JPInternational University of Health and Welfare · JPJichi Medical University · JPKobe University · JPKyoto University · JPNakamura Gakuen University · JPNippon Medical School · JPSumitomo Hospital · JPTaoka Hospital · JPUniversity of Toyama · JPYamaguchi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundJELIS was a large-scale clinical trial that investigated the effects of eicosapentaenoic acid (EPA) on coronary artery disease (CAD). In this paper, the data of patients registered in JELIS were analysed to compare the incidence of CAD between patients with impaired glucose metabolism (IGM) and normoglycemic (NG) patients. The effect of EPA on the incidence of CAD in patients with IGM was also assessed.

methodsThe 18,645 hypercholesterolemic patients registered in JELIS were divided into two groups. One group consisted of patients with IGM (n=4565), which included the patients who had diabetes mellitus and patients who had a fasting plasma glucose of 110mg/dL or higher, either at the time of registration or after 6 months. The other group consisted of NG patients (n=14,080). CAD incidence of the two groups over the average 4.6-year follow-up period was compared, and the effect of EPA was assessed.

resultsCompared to NG patients, IGM patients had a significantly higher CAD hazard ratio (1.71 in the non-EPA group and 1.63 in the EPA group). The treatment with EPA resulted in a 22% decrease in the CAD incidence (P=0.048) in IGM patients and an 18% decrease (P=0.062) in NG patients.

conclusionsIt was found that the CAD risk in IGM patients is higher than in NG patients, and that highly purified EPA is very effective in decreasing the incidence of CAD among Japanese IGM patients, even though the intake of fish is high.

Indexed as

AdultAgedCoronary Artery DiseaseDiabetes MellitusEicosapentaenoic AcidFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaJapanMaleMiddle AgedEicosapentaenoic AcidHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID19447387
OpenAlexW2007616354

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.